Survival and Clinical Outcomes of Advanced-Stage Colorectal Adenocarcinoma: A Single Center Retrospective Study
Keywords:
colorectal cancer, progression free survival, overall survival, prognostic factorAbstract
Objective: The primary endpoint of this study was progression free survival (PFS) and secondary endpoint was overall survival (OS) outcomes, prognostic factor, chemotherapy toxicity of advanced stage colorectal cancer (CRC)
Methods: This retrospective study included colorectal cancer patients operated in Nakhonpathom Hospital during the period 1 October 2019 to 30 September 2024. In this descriptive study, data were analyzed using frequency, percentage, mean, standard deviation, and compared correlation using t test and chi-square test. The survival rate was reported using the Kaplan-Meier test. Between group comparisons were made using log-rank test and Cox regression analysis.
Result: The median progression free survival in advanced-stage colorectal cancer was 6 months (HR 1.26; 95% CI 0.88–1.81; p = .206) and overall survival in advanced-stage colorectal cancer was 12 months (HR 0.99; 95% CI 0.67–1.46; p = .964)
Conclusions: The real-world study of advanced-stage colorectal cancer (n = 150) demonstrate that 5 years progression free survival was 8 % and overall survival was 24%. liver metastasis was associated with shorter progression free survival and overall survival.
References
Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91. doi:10.1136/gutjnl-2015-310912
Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233–54. doi:10.3322/caac.21772
Shin A, Jung KW, Won YJ. Colorectal cancer mortality in Hong Kong of China, Japan, South Korea, and Singapore. World J Gastroenterol. 2013;19(7):979–83. doi:10.3748/wjg.v19.i7.979
Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, et al. European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Ann Oncol. 2018;29(4):1016–22. doi:10.1093/annonc/mdy033
Moghimi-Dehkordi B, Safaee A. An overview of colorectal cancer survival rates and prognosis in Asia. World J Gastrointest Oncol. 2012;4(4):71–5. doi:10.4251/wjgo.v4.i4.71
Moghimi-Dehkordi B, Safaee A, Zali MR. Prognostic factors in 1,138 Iranian colorectal cancer patients. Int J Colorectal Dis. 2008;23(7):683–8. doi:10.1007/s00384-008-0463-7
Ghazali AK, Musa KI, Naing NN, Mahmood Z. Prognostic factors in patients with colorectal cancer at Hospital Universiti Sains Malaysia. Asian J Surg. 2010;33(3):127–33. doi:10.1016/S1015-9584(10)60022-X
Ratto C, Sofo L, Ippoliti M, Merico M, Doglietto GB, Crucitti F. Prognostic factors in colorectal cancer. Literature review for clinical application. Dis Colon Rectum. 1998;41(8):1033–49. doi:10.1007/BF02237397
Wang J, Li S, Liu Y, Zhang C, Li H, Lai B. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis. Cancer Med. 2020;9(1):361–73. doi:10.1002/cam4.2673
Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, et al. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol. 2023;7(1):16. doi:10.1038/s41698-023-00353-4
Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018;29(1):44–70. doi:10.1093/annonc/mdx738
Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10–32. doi:10.1016/j.annonc.2022.10.003
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041–7. doi:10.1016/s0140-6736(00)02034-1
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–47. doi:10.1200/JCO.2000.18.16.2938
Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol. 2008;26(36):5910–7. doi:10.1200/JCO.2008.16.7759
Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26(12):2006–12. doi:10.1200/JCO.2007.14.9898
Ng SL, Burns WI, Snyder RD, Newnham GM, McLachlan SA, Liew D, et al. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels. Asia Pac J Clin Oncol. 2012;8(2):172–9. doi:10.1111/j.1743-7563.2011.01486.x
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ลิขสิทธิ์บทความเป็นของผู้เขียนบทความ แต่หากผลงานของท่านได้รับการพิจารณาตีพิมพ์ลงวารสารแพทย์เขต 4-5 จะคงไว้ซึ่งสิทธิ์ในการตีพิมพ์ครั้งแรกด้วยเหตุที่บทความจะปรากฎในวารสารที่เข้าถึงได้ จึงอนุญาตให้นำบทความในวารสารไปใช้ประโยชน์ได้ในเชิงวิชาการโดยจำเป็นต้องมีการอ้างอิงถึงชื่อวารสารอย่างถูกต้อง แต่ไม่อนุญาตให้นำไปใช้ในเชิงพาณิชย์
